Together, these results suggested that the FOXD1/p21/CDK2/Rb axis has an important impact on the proliferation of HNSCC and that the CDK2 inhibitor reverses the malignancy of FOXD1-overexpressing HNSCC cells to a certain extent. The gene discussed is CDK2; the disease is head and neck squamous cell carcinoma.